莫西沙星治疗难治复治多耐药肺结核的Meta分析  

Meta Analysis of Moxifloxacin for Refractory,Recurrent,Multi-drug Resistant Pulmonary Tuberculosis

作　　者：熊晗晖[1] 张丽娜[1] 

机构地区：[1]中国人民解放军总参谋部总医院药剂科,北京100091

出　　处：《中国医药导刊》2011年第3期488-490,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:以莫西沙星治疗难治复治多耐药肺结核的疗效优劣和安全性为评价目标。方法:检索Medline(1950～2009)、外文全文生物医学期刊(FJIS,1995～2008)、中国医院数字图书馆(CNKI,1994～2008)、中国生物医学文献数据库(CBMdisc,1977～2008)、WHO EML等数据库和网站中所有莫西沙星治疗难治复治多耐药肺结核随机对照临床试验,按照《药品文献评价指导原则》同时采用Cochrane协作网提供的RevMan 4.2.10软件分析数据。结果:最终纳入7个RCT。Meta分析结果显示,莫西沙星治疗组与对照组相比,痰菌转阴率[RR=1.11,95%CI(1.03,1.19)],临床有效率[RR=1.14,95%CI(1.04,1.25)]的差异均有统计学意义。不良反应主要为神经系统症状、消化系统反应、肝功能损害以及光敏反应。结论:现有证据表明,莫西沙星用于难治、复治、多耐药肺结核治疗,有助于痰菌转阴。受本评价纳入研究质量所限,尚需开展更多高质量的研究进一步分析。Objective：To assess the effectiveness and security of Moxifloxacin for refractory, recurrent, multi-drug resistant pulmonary tuberculosis.Methods：We searcher the Medline（1950-2009）,FJtS（1995-2008）,CNKI（1994-2008）,CBMdisc（1977-2008）,WHO EML to collect randomized controlled trails（RCTs） which is moxifloxacin for refractory, recurrent,multi-drug resistant pulmonary tuberculosis.Results： The data was analyzed by using The Cochrane Collaboration＇s RevMan 4.2.10 software. 7 RCTs were included.Compared with control group,Moxifloxacin was more effective in focus absorption[RR=l.ll,95%Cl（1.03,1.19）]and cavitates decrease[RR=l.14,95%CI（l.04,1.25）]. ADR as nervous system,digestive system,liver function damage,photosensitivity was recovery by treatment.Conclusion：Moxifloxacin for refractory, recurrent,multi-drug resistant pulmonary tuberculosis was useful for focus absorption and cavitates decrease.However, This systematic review was restricted by the quality of data and we need collect more evidence.

关 键 词：莫西沙星 难治 复治 多耐药 META 分析 

分 类 号：R521[医药卫生—内科学] R969.3[医药卫生—临床医学]